Chief Medical Officer

Mohamed Eid, MD

A physician by background, Mohamed has 30 years’ experience in endocrine, diabetes, metabolic and cardiovascular medicine, clinical pharmacology, and clinical research. He has been heavily involved in global drug development, regulatory submissions, and commercialization of first-in-class GLP-1 based therapies, novel insulin analogs, SGLT-2 inhibitors, and other cardiovascular and metabolic medicines. Mohamed joined Verdiva Bio from Boehringer Ingelheim Pharmaceuticals where he was US Head of Clinical Development and Medical Affairs for Cardiovascular, Kidney, and Metabolic Medicines. Prior to that, he spent 16 years at Novo Nordisk working across US, Europe, Canada, Japan & Korea as Corporate Vice President and Head of Clinical, Medical, & Regulatory, Chief Medical Officer, and other roles. His earlier career included senior roles at Takeda Pharmaceuticals, and Bristol-Myers Squibb.

Mohamed holds a medical doctoral degree and two master’s degrees, majoring in Clinical Research and in Healthcare Administration from the University of Minnesota. He is currently Affiliate Assistant Professor at the University of Minnesota School of Public Health.